

## Notice of Quarterly Investor Conference Call

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces that its Appendix 4C Cash Flow Report and Management Quarterly Activities Report for the three months ended 31 December 2022, will be released on Monday, 30 January 2023.

The Company will host an investor conference call at 11.00am AEDT on Monday, 30 January 2023 with Dr Thomas Duthy, Executive Director.

Details of the call are set out below.

In order to pre-register for the conference call and avoid a queue when calling, please follow the link below. You will be given a unique pin number to enter when you call which will bypass the operator and give you immediate access to the event.

<https://s1.c-conf.com/diamondpass/10028298-fj84y1.html>

Alternatively, you may dial in with the following details, approximately five minutes before the scheduled start time and provide the Conference ID to an operator.

Conference ID: **10028298**

### Participant Dial-in Numbers:

Australia Toll Free: 1800 908299  
Australia Local: +61 2 9007 8048  
New Zealand: 0800 452 795  
Canada/USA: 1855 624 0077  
Hong Kong: 800 968 273  
Japan: 006 633 868 000  
China: 108 001 401 776  
Singapore: 800 101 2702  
United Kingdom: 0800 0511 453

### Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

### Investors:

Dr Thomas Duthy  
Executive Director  
[td@neurotechinternational.com](mailto:td@neurotechinternational.com)  
+61 (0)402 493 727

### Media:

Lisa Blake  
LBPR  
[lisa@lbpr.com.au](mailto:lisa@lbpr.com.au)  
+61 (0) 429 976 718

## About Neurotech

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days and 20 weeks of treatment with NTI164. The Company will commence a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. Neurotech plans to conduct additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with cerebral palsy during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.